ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1278

Combined Positron Emission Tomography and Magnetic Resonance Imaging in Assessing Gastrointestinal Involvement in Systemic Sclerosis: A Pilot Study

Sue-Ann Ng1, Stephanie Marchesseau2, Yu Tien Wang3, Josh Schaefferkoetter2, Wanying Xie4, David Ng4, John Totman2 and Andrea HL Low1, 1Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Duke-National University of Singapore, Singapore, Singapore, 2Clinical Imaging Research Center, A*STAR & National University of Singapore, Singapore, Singapore, Singapore, 3Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore, Singapore, 4Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore, Singapore, Singapore

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Magnetic resonance imaging (MRI), positron emission tomography (PET) and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic sclerosis (SSc), a multi-organ fibrotic disease, affects the gastrointestinal tract (GIT) in 90% of patients. An urgent unmet need in the management of SSc GIT involvement is the availability of non-invasive investigations for early diagnosis and monitoring. Development of a new MRI sequence, T1 MOLLI (modified look-locker inversion recovery) mapping, has been applied to cardiac imaging, which enables detection and quantification of diffuse fibrosis without contrast. In this pilot study comparing SSc patients with healthy controls, we investigate FDG-PET/MRI in diagnosing SSc GIT involvement, hypothesizing that (i) MRI T1 MOLLI values, denoting fibrosis, is higher in SSc patients than healthy controls, and (ii) PET detects bowel inflammation associated with early mild GIT involvement.  

Methods:

Ten patients fulfilling the 2013 ACR/EULAR criteria for SSc and 10 healthy age and sex matched controls underwent scanning. SSc patients either had early SSc <3 years and asymptomatic to mild GIT symptoms (Group A, n=5), or moderate to severe GIT symptoms regardless of disease duration (Group B, n=5), as determined by a validated questionnaire (Table 1). All subjects fasted 6 hours prior and had non-spicy low-residue diet 3 days prior. SSc patients underwent PET-MRI scan, 60 minutes after injection of 6mCi FDG tracer and immediately after injecting 10mg hyoscine butylbromide (reduce peristalsis). Breath-hold native T1 MOLLI mapping was acquired. Controls underwent the same MRI protocol. FDG uptake was quantified by specific uptake value (SUV). Student t-test and box plots were used to evaluate statistical significance (p<0.05).

Results:

Majority were females with a mean age of 48 years. Mean T1 values for the large and small bowels were higher in SSc patients than healthy controls (large bowel: 1206±148ms vs 869±192ms respectively, p<0.001; small bowel: 1425±245ms vs 1150±115ms respectively, p=0.005) (Table 1).

All SSc patients had high PET uptake in the bowel (on average 25% of their total bowel had SUV >1.5). PET SUV values in the large and small bowels were higher in Group A (mean GIT score 0.11) than Group B (mean GIT score 0.57) patients. In the large bowel, T1 values were higher in the regions of inflamed bowel, as defined by PET SUV >1.5 (Figure 1).

Conclusion:

 

Our preliminary results suggest the feasibility of using T1 MOLLI to evaluate bowel fibrosis. FDG-PET showed uptake in all SSc cases, with increased bowel inflammation occuring in patients with early mild disease. FDG-PET/MRI is potentially a useful diagnostic and monitoring tool for SSc GIT disease.

 

 

Table 1

  Group A (n=5) Group B (n=5) All SSc patients (n=10) Controls (n=10)
Demographic and clinical features
Female sex, n (%) 5 (100%) 4 (80%) 9 (90%) 9 (90%)
Age, years 42.4 ± 15.9 54.0 ± 5.7 48.2 ± 12.8 48.0 ± 12.7
Limited/Diffuse SSc, n 2/3 5/0 7/3 Not applicable
Mean disease duration from Raynaud’s phenomenon onset, years 2.6 ± 0.8 5.0 ± 4.3 3.8 ± 3.2 Not applicable
Mean disease duration from non-Raynaud’s phenomenon onset, years 3.1 ± 1.0 4.7 ± 3.6 3.9 ± 2.6 Not applicable
Total GIT score 0.11 ± 0.07 0.57 ± 0.29 0.34 ± 0.32 0
T1 MOLLI and PET findings
T1 (large bowel) (ms) 1218 ± 142 ¶   1193 ± 170 ¶   1206 ± 148 ¶   869 ± 192
T1 (small bowel) (ms) 1335 ± 112 ¶   1516 ± 320 ¶   1425 ± 245 ¶   1150 ± 115  
PET SUV (large bowel) 1.31 ± 0.30   1.11 ± 0.19   1.21 ± 0.26 Not applicable
PET SUV (small bowel) 1.31 ± 0.35   1.19 ± 0.33   1.25 ±0.33 Not applicable
Total GIT: Total Gastrointestinal Tract (version 2.0) score, from University of California Los Angeles Scleroderma Clinical Trials Consortium ¶ p < 0.05 versus controls

Figure 1

PICTURE 4

 


Disclosure: S. A. Ng, None; S. Marchesseau, None; Y. T. Wang, None; J. Schaefferkoetter, None; W. Xie, None; D. Ng, None; J. Totman, None; A. H. Low, None.

To cite this abstract in AMA style:

Ng SA, Marchesseau S, Wang YT, Schaefferkoetter J, Xie W, Ng D, Totman J, Low AH. Combined Positron Emission Tomography and Magnetic Resonance Imaging in Assessing Gastrointestinal Involvement in Systemic Sclerosis: A Pilot Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/combined-positron-emission-tomography-and-magnetic-resonance-imaging-in-assessing-gastrointestinal-involvement-in-systemic-sclerosis-a-pilot-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/combined-positron-emission-tomography-and-magnetic-resonance-imaging-in-assessing-gastrointestinal-involvement-in-systemic-sclerosis-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology